期刊文献+

^(18)F-FDG PET/CT显像对淋巴瘤的诊断及疗效观察 被引量:2

下载PDF
导出
摘要 目的:探讨18F-脱氧葡萄糖(FDG)PET/CT显像对淋巴瘤的诊断及疗效评价。方法:71例疑似淋巴瘤的患者行18F-FDG PET/CT显像及病理学检查以评析18F-FDG PET/CT显像对淋巴瘤的诊断价值。其中22例淋巴瘤患者在治疗后3~6个月行第二次PET/CT显像,前后两次PET/CT显像均勾画感兴趣区域(SOI区)2~3个,测定其SUV值,取其平均值(SUVmax>2.5为阈值)。对比治疗前后同一SOI区SUV值的改变,以评价其疗效。结果:71例疑似淋巴瘤患者中,病理学检查阳性者58例,PET/CT显像阳性者59例,两者一致阳性数为58例,两者一致的阴性数为11例。18例患者治疗后,第二次PET/CT显像示大部分原高代谢的区域恢复正常,残留的区域SUV值较前减小,2例治疗后第二次PET/CT检查,高代谢区域已经完全恢复正常,考虑肿瘤被抑制。2例治疗后,复查PET/CT无改变,予以调整治疗方案。3例在治疗后二年随访PET/CT示肿瘤复发。结论18F-FDG PET/CT显像对淋巴瘤诊断的灵敏度,特异度分别为98.3%(58/59),91.7%(11/12)。治疗前后SUV值的改变有统计学意义(t=3.73,P=0.001)。故可以认为SUV值结合CT结构形态的观察对淋巴瘤的诊断具有重要的价值。同时治疗前后SUV值的改变可作为疗效观察,随访以及判断预后的一个可靠、敏感的指标。
出处 《新疆医学》 2010年第2期1-3,共3页 Xinjiang Medical Journal
  • 相关文献

参考文献9

  • 1谢毅.淋巴瘤.内科学.6版.北京:人民卫生出版社,2005:619-630.
  • 2贾志云,邓候富,青春.^(18)F-FDGPET或PET/CT显像在淋巴瘤中的应用[J].中国临床医学影像杂志,2008,19(2):125-127. 被引量:17
  • 3李向东,尹吉林,王卓才,王欣璐,全江涛,欧阳习,蔡超,郑辉.^(18)F-FDG PET/CT显像诊断恶性淋巴瘤的临床价值[J].广东医学,2007,28(7):1090-1091. 被引量:3
  • 4田嘉禾.PET在淋巴瘤诊断方面的应用[J].实用肿瘤杂志,2005,20(2):102-105. 被引量:7
  • 5Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:prevalence and scan interpretation.Nucl med Commun,2005,26(8):689-694.
  • 6Bare R,Hostman K,Altehoefer C,et al.18F-FDG PET to assess local effect of radiation or chemotherapy in patients with malignant lymphoma.J Nucl Med,1991.27:56-58.
  • 7Hoekstra OS,Ossenkoppele GJ,Golding R,et al.Early treatment response in malignant lymphoma as determined by planar 18F-fluorodeoxyglucose scintigraph.J Nucl Med,1993,34:1706-1710.
  • 8Spaepen K,Stroobants S,Dupont P,et al.Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.Ann Oncol,2002,13:1356-1363.
  • 9Dittmann H,Sokler M,Kollmannsberger C,et al.Comparison of 18F-FDG PET with CT SCanS in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.Oncol Rep,2001,8:1393-1399.

二级参考文献26

  • 1管樑 ,Rebecca Elstrom ,Zhuang Hong-ming ,Stephen J.Schuster ,朱承谟 ,Abass Alavi .^(18)F-FDG PET显像对不同亚型淋巴瘤的诊断价值[J].中华核医学杂志,2004,24(4):207-209. 被引量:9
  • 2王辉,江旭峰,王超,李彪,李培勇,朱承谟.^(18)F-FDG PET与^(67)Ga全身显像对淋巴瘤分期的临床价值[J].中华核医学杂志,2005,25(2):100-101. 被引量:7
  • 3VAN DEN BERG H,VERHUST L,BEHRENDT H,et al.Persistent mediastinal mass is not indicative of recurrence after chemotherapy only in paediatric Hodgkin's disease[J].Br J Haematol,2000,109:104-108.
  • 4HOH C K,GLASPY J,ROSEN P,et al.Whole-body 18F-FDG PET imaging for staging of Hodgkin'disease and lymphoma[J].J Nucl Med,1997,38:343-348.
  • 5STUMPE K D,URBINELLI M,SSTEINERT H C,et al.Whole -body positron emission tomography using fluorodeoxyglucose for staging of lymphoma:effectiveness and comparison with computed tomography[J].Eur J Nucl Med,1998,25:721-728.
  • 6SPAEPEN K,STROOBANTS S,DUPONT P,et al.Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients eith aggressive non-Hodgkin's lymphoma[J].Ann Oncol,2002,13:1 356-1 363.
  • 7Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments[J]. Leukemia Lymphoma, 2007, 48(2): 270-282.
  • 8Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse [J]. Eur J Nucl Meal Mol Imaging, 2003, 30(Suppl 1): S89-S96.
  • 9Furth C, Denecke T, Steffen I, et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease [J]. J Pediatr Hematol/Oncol, 2006, 28 (8): 501- 512.
  • 10Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma[J]. Br J Haematol, 2006, 135(3): 293-302.

共引文献23

同被引文献25

  • 1田嘉禾.PET在淋巴瘤诊断方面的应用[J].实用肿瘤杂志,2005,20(2):102-105. 被引量:7
  • 2Cerci J J,Trindade E,Buecheri V,et al. Consistency of FDG-PET accu-racy and cost -effectiveness in initial staging of patients with Hodgkinlymphoma across jurisdictions^]. Clin Lymphoma Myeloma Leuk, 2011,11(4):314-320.
  • 3Wu X, Dastidar P, Pertovaara H,et al. Early Treatment Response Evalu-ation in Patients with Difuse Large B -Cell Lymphoma -A Pilot StudyComparing Volumetric MRI and PET/CT[J]. Mol Imaging Biol,2010,25(8):22-24.
  • 4Crocchiolo R,Fallanca F’Giovacchini G,et al. Role of 18FDG-PET/CTin detecting relapse during follow-up of patients with Hodgkin's lym-phoma[J]. Ann Hematol, 2009,88 (12) : 1229-1236.
  • 5Baba S,Abe K,lsoda T,et al. Impact of FDG-PET/CT in the manage-ment of lymphoma[J]. Ann Nucl Med,2011,29( 10) :Epub ahead of print.
  • 6Hutchings M, Barrington S F. PET/CT for therapy response assessmentin lymphoma[J]. J Nucl Med ,2009,50(Suppl 1 ) :21-30.
  • 7Cheson BD’Pfistner B’Juweid ME ,et al. Revised response criteria formalignant lymphoma[J]. J Clin Oneol, 2007,25 : 579-586.
  • 8孙菁,周进祝.内科学[M].7版.北京:科学出版社,2003.
  • 9Haioun C, Itti E, Rahmouni A, et al. 18F fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggres- sive lymphoma: an early prognostic tool for predicting patient outcome[J]. Blood, 2005, 106(4) : 1376-1381.
  • 10Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F- FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy[J]. J Nucl Med, 2009, 50(4):527-533.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部